MORF-627 [CAS 2412688-16-3]

MORF-627 is a selective, orally active inhibitor for integrin αvβ6 with an IC50 of 9.2 nM measuring by human serum ligand binding assay. MORF-627 inhibits αvβ6-mediated TGF-β1 activation with an IC50 of 2.63 nM, inhibits SMAD2/3 phosphorylation with an IC50 of 8.3 nM. MORF-627 ameliorates the Bleomycin -induced mouse lung fibrosis[1].

[2412688-16-3]

C31H40FN3O4

537.67

OC([C@@H](N1C[C@@H](CC1)OCCCCC(N2)=CC=C3C2=NCCC3)C4=C(C=CC(F)=C4)[C@@H]5CCC6(CO5)CC6)=O

Integrin; TGF-beta/Smad

αvβ6

-20°C, 3 years; 4°C, 2 years (Powder)

Room Temperature